http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002168753-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0004 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4711 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate | 2001-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ebcb2ef600b9d9c0f5594ba16231523c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a9c9627d563ed56655a54905e13837e |
| publicationDate | 2002-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2002168753-A1 |
| titleOfInvention | In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of Alzheimer's and Prion diseases |
| abstract | Co-incubation of an amyloid protein with sulfated macromolecules as a method for the formation of amyloid plaques. The amyloid protein may be the beta-amyloid protein or the prion protein or the like. Amyoid plaque formation in one embodiment proceeds in vitro and desireably produces amyloid plaques that stain with Congo red and demonstrate a maltese-cross pattern when viewed under polarized light. The method also produces amyloid plaques that demonstrate an “amyloid star” appearance when viewed by transmission electron microscopy. n Sulfated macromolecules include a sulfated proteoglycan selected from the group consisting of perlecan, ˜220 kilodalton heparan sulfate proteoglyean, glypican, cerebroglycan, aggrecan, synaptoglycan (SV2PG), syndecan, N-syndecan (also known as syndecan-3), syndecan-1, syndecan-4, neurocan, phosphacan, decorin, biglycan, versican, amphiglycan, lumican, PG-M, PG-M (3), agrin, betaglycan, claustrin, brevican, appican, epican, neuroglycan-C, and fragments thereof. Thw sulfated macromolecule may be a sulfated glycosaminoglycan selected from the group consisting of heparin, heparan sulfate, dermatan sulfate, chondroitin sulfate, keratan sulfate, and fragments thereof. n An in vivo assay is also presented for selecting a candidate therapeutic agent for inhibiting or disrupting amyloid plaque deposition or persistence. The assay includes a) pre-forming congophilic maltese-cross amyloid plaques in vitro following incubation of an amyloid protein and a selected sulfated macromolecule, b) using a first cannula and osmotic pump to continuously infuse for a selected duration the pre-formed congophilic maltese-cross amyloid plaques into a tissue or organ, c) changing the first cannulae and osmotic pump with a second cannulae and osmotic pump to administer the candidate therapeutic, and d) detecting the candidate therapeutic's ability to disrupt, reduce, or eliminate congophilic maltese-cross amyloid plaque deposition/persistence in the tissue or organ. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004260076-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007191330-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004152760-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109381452-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109381453-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8163957-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7514583-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8754133-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003017998-A1 |
| priorityDate | 1998-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 651.